Connect Biopharma Holdings Ltd - Asset Resilience Ratio
Connect Biopharma Holdings Ltd (CNTB) has an Asset Resilience Ratio of 25.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CNTB total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Connect Biopharma Holdings Ltd's Asset Resilience Ratio has changed over time. See Connect Biopharma Holdings Ltd (CNTB) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Connect Biopharma Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CNTB stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $16.94 Million | 25.14% |
| Total Liquid Assets | $16.94 Million | 25.14% |
Asset Resilience Insights
- Very High Liquidity: Connect Biopharma Holdings Ltd maintains exceptional liquid asset reserves at 25.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Connect Biopharma Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Connect Biopharma Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Connect Biopharma Holdings Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Connect Biopharma Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.28% | $15.48 Million | $101.28 Million | +5.23pp |
| 2023-12-31 | 10.05% | $12.65 Million | $125.89 Million | -32.14pp |
| 2022-12-31 | 42.18% | $74.67 Million | $177.01 Million | +42.18pp |
| 2021-12-31 | 0.00% | $677.10 | $291.39 Million | -1.20pp |
| 2020-12-31 | 1.20% | $2.00 Million | $166.19 Million | -7.02pp |
| 2019-12-31 | 8.22% | $4.44 Million | $54.05 Million | +7.69pp |
| 2018-12-31 | 0.54% | $371.01K | $69.29 Million | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as a… Read more